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Aim: Neonatal diabetes is rare and treatment is challenging. We present aspects on treatment, 
genetics and incidence.  
Method: This was a prospective cohort study including all cases in our study area in Sweden. 
We compared with data from the National Diabetes Registry, the Neonatal Quality Register and 
the National Patient Register. 
Results: In the 19-year study period 1 January 1998 to 31 December 2016, we treated seven 
infants, five of them boys. Six patients used a subcutaneous insulin pump, and the smallest 
patient started at a weight of 938 grams. Most important was for the pump to deliver minute 
doses of insulin and the design of cannulas and tubing. All patients could stop insulin 
treatment at 17-145 days of age. One patient relapsed at age 4.5 years. Four patients used the 
insulin pump after discharge. A mutation was identified in five patients and this included all 
patients born after 30 weeks of gestation. The incidence of neonatal diabetes was 2/100000, 
higher than previously estimated for Europe. Similar but lower incidences were reported in 
the registries. 
Conclusion: Insulin pumps were safe in neonatal diabetes. All seven cases were transient. 
Neonatal diabetes was more common in our area than reported from Europe.  
 
Keywords: ABCC8; continuous glucose monitoring; insulin pump; neonatal diabetes 
mellitus; patient-centred care 
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Key notes (70w) 
 Neonatal diabetes is rare but from this cohort of seven infants we suggest that the 
incidence is higher than previously described  
 Insulin pumps were used from a patient weight of 1000 grams where the ability of the 
pump to deliver small doses of insulin and the size, length and insertion angle of 
tubing and cannula was important 
 The technical devices enabled parents to continue treatment of their child at home  
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INTRODUCTION 
Neonatal diabetes mellitus (NDM) is defined as diabetes with an onset before six months of 
age. NDM can either be transient (TNDM) or remain as permanent neonatal diabetes mellitus 
(PNDM). The prevalence of PNDM has been reported as one in 215000 children in Slovakia 
(1) and one in 260000 children in three other European countries; the UK, the Netherlands 
and Poland (2). Other authors have proposed that NDM is less rare, with the minimal 
incidence of NDM  (PNDM and TNDM) in Italy estimated to one in 90000 (3). Also, a higher 
incidence of PNDM of one in 40000 has been reported from Oman where consanguineous 
marriages are more common (4, 5). 
Among patients undergoing genetic testing, PNDM constitute 40-50% of cases of NDM (6). 
More than 30 different genetic causes have been described in any of the biological pathways 
that regulate glucose homeostasis by affecting mechanisms of insulin release or pancreatic 
development and sustainability. Some of the more common mutations can result in both 
TNDM and PNDM (6, 7). Children with TNDM can relapse and get diabetes again later in 
life (6, 8). In contrast to type 1 diabetes mellitus, autoantibodies are not identified in NDM 
except for in very rare syndromes affecting the immune system (9). 
Hyperglycaemia in a preterm infant can be the result of immaturity, insulin resistance, 
infection or treatment, for example with intravenous glucose or steroids (10). Therefore, 
hyperglycaemia in a newborn infant that calls for treatment with insulin for at least 14 days is 
often used as a practical definition of NDM (11). 
Children with NDM are often born small for gestational age. The likeliness of a mutation is 
reported to be high in preterm children, and even higher in full-term children with NDM. In a 
large study, mutations were found in 97/146 (66%) of preterm infants with NDM compared to 
501/604 (83%) in children born ≥37 weeks (12). Although the genetic defect obviously was 
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present at birth, some children present at a few weeks or months of age with failure to thrive, 
dehydration or ketoacidosis (8). 
Children with mutations in either of the genes, ABCC8 or KCNJ1, encoding the potassium 
channel of the pancreatic beta-cell membrane, as well as children with NDM resulting from 
abnormalities in a region of chromosome six, 6q24, can be successfully treated with oral 
sulphonylurea or other oral anti-diabetic drugs (8, 13, 14). However, until results of genetic 
testing are available, insulin will be necessary to ensure growth and development in all infants 
with NDM. 
Insulin pump treatment is in our Paediatric Diabetes Unit at Karolinska University Hospital, 
Sweden,  standard care for type 1 diabetes mellitus with 65% of all patients aged 0-17 years in 
Sweden using an insulin pump (15).  In our unit, insulin pumps are almost always used in 
onset of type 1 diabetes mellitus below two years of age.  To our knowledge there are no 
controlled trials comparing different modes of delivering insulin to patients with NDM.  
There are practical challenges when treating children with NDM with minute volumes of 
insulin to optimise metabolic control and yet avoid potentially dangerous hypoglycaemic 
events.  Also, complications associated with the use of intravenous lines make the use of 
subcutaneous administration of insulin via an insulin pump an interesting alternative. In a 
review, Rabbone et al compiled information from 29 cases of NDM treated with insulin 
pumps, the smallest around 1200 grams body weight, and concluded that their review 
indicated that treatment with insulin pumps is safe and effective in NDM, and other studies 
have also contributed to this conclusion (16-18). Likewise, continuous glucose monitoring 
(CGM) using a subcutaneous sensor represents an attractive mode of glucose control in 
neonates where frequent blood sampling and matching with feeding patterns can be both 
difficult and disturbing for the child in the neonatal intensive care unit (NICU). We also 
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hypothesised that parents could be trained to handle the insulin pumps and CGM similar to 
standard practice for parents of children with type 1 diabetes mellitus.  Parental involvement 
would shorten the period needed for hospitalisation and empower the parents in their care for 
their infant and encourage patient-centred care. 
In this observational longitudinal prospective study, we have compiled information from 
seven newborn children with diabetes that we believe to constitute the total number of cases 
in our area for the 19-year study period. The aim of this study was to present practical aspects 
of treatment as well as results of genetic analyses for the patients. We also estimate the 
incidence on NDM in our setting and compare our data to the incidence of NDM reported in 
three Swedish quality registers: the Swedish National Diabetes Registry Swediabkids that 
includes almost 100% of children with all forms of diabetes in Sweden (15), the Swedish 
Neonatal Quality Register that collects information of all patients in neonatal care (19), and 
the National Patient Register by the National Board of Health and Welfare that collects data 
on inpatient diagnoses from all hospitals in Sweden. 
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PATIENTS AND METHODS 
Study area 
The health care of the capital city of Sweden, Stockholm, is administered by the Stockholm 
Region for an area with 2.3 million inhabitants (20). Deliveries almost exclusively take place 
at hospitals. The Karolinska University Hospital in three geographic locations, Danderyd, 
Huddinge and Solna, constitute three of the four paediatric university hospitals with neonatal 
intensive care in the region. All patients with NDM born at Karolinska University Hospital 
were treated at the hospital in Huddinge. Also, all patients that were born at Södertälje 
Hospital and in need of neonatal intensive care were referred to Karolinska University 
Hospital Huddinge. 
Study population 
Children with NDM that were treated from 1 January 1998 to 31 December 2016 at 
Karolinska University Hospital Huddinge were the study population.  
Study cohort 
This is an observational study of a clinical cohort. Seven children fulfilled the inclusion 
criteria: an onset of diabetes before six months of age and treatment with insulin for more 
than 14 days. We believe these patients constitute all cases in the hospitals that would have 
referred patients to us. A girl born in 1998 in gestational week 26 with a birth weight of 872 
grams made us initiate this study. She was treated with intravenous insulin for 11 days. An 
insulin pump was not used and genetic analysis was not performed. As the patient did not 
fulfil inclusion criteria she was not included in this study, but the case prompted us to start 
collecting information on patients with NDM from 1998 onwards.  
Insulin pumps and insulin 
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During the study period two different insulin pumps were used for NDM; MiniMed Paradigm 
Real-Time and Paradigm VEO (Medtronic, Kista, Sweden). Pumps were chosen for reliability 
and ability to deliver small volumes, 0 or 0.025 U of insulin per hour.  We connected the 
pump to the patient with a MiniMed Silhouette infusion set (Medtronic, Kista, Sweden), using 
shortest available tubing length (45cm) and smallest available cannula (13mm) for all patients 
(Table 1). This infusion set was chosen as it allows a 30-45 degrees insertion angle, or less, 
aiming at placing the cannula in the thin layer of subcutaneous fat between the skin and the 
muscular fascia beneath.  
In the study period three different brands of insulin were used in the pumps: short-acting 
Insulin Human, Humulin Regular 100 U/ml (Eli Lilly Sweden, Solna, Sweden), and rapid-
acting insulins Insulin Lispro, Humalog 100 U/ml (Eli Lilly Sweden, Solna, Sweden) and 
Insulin Aspart, Novorapid 100 U/ml (Novo Nordisk Scandinavia AB, Malmö, Sweden). 
Initially we used a 2-step procedure to give 1 U/ml. For the later patients, Insulin Lispro was 
diluted with a diluent provided by the manufacturer in a one-step dilution 1:10 to give insulin 
10 U/ml (Table 1).  
Subcutaneous glucose monitoring 
For the first patient included in the study in 2007 we used microdialysis to monitor 
subcutaneous glucose (CMA Microdialysis AB, Kista, Sweden). Ongoing development of 
devices made us use different systems for CGM in the study period: DexCom G4 and 
DexCom G5 (Nordicinfu Care AB, Nacka Strand, Sweden) and Guardian RealTime system 
with MiniMed Sof-Sensor or MiniLink Enlite sensor (Medtronic, Kista, Sweden). Plasma-
glucose was analysed for calibration of CGM as per manufacturer’s advice, usually twice a 
day. CGM devices were chosen due to availability and perceived reliability. For the later 
cases in the cohort we also analysed down-loaded comprehensive data of the CGM using a 
web-based interface (CareLink, Medtronic, Kista, Sweden). 
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Investigations 
Data on birth weight, gestational age, sex, the parents’ country of birth, treatment with insulin, 
use of insulin pumps and CGM was recorded. Analyses of plasma-glucose, serum-insulin, 
plasma-glucagon, faeces-elastase, serum-C-peptide and serum-autoantibodies were performed 
at the Karolinska University Hospital laboratory, Stockholm and Skånes Universitetssjukhus, 
Malmö, Sweden. Genetic analyses were performed at Molekylargenetisches Labor, 
Weisswasser, Germany, University of Southampton, Wessex, United Kingdom, and Skånes 
Universitetssjukhus, Malmö, Sweden and for the later cases at the University of Exeter, 
Exeter, United Kingdom using Sanger sequencing, 6q24 methylation analysis, and targeted 
next-generation sequencing of known neonatal diabetes genes. 
All patients were followed at the Pediatric Diabetes Unit after discharge from the NICU. After 
terminating insulin treatment, parents were alerted to react to signs of diabetes and regular 
clinical evaluation with tests of glycosylated haemoglobin and plasma-glucose were 
performed to determine whether diabetes re-occurred in children with TNDM. 
Incidence of neonatal diabetes mellitus 
To estimate the incidence of NDM, we compared the number of cases with the total number 
of deliveries. We also compared our data with data from three national quality registers. 
Firstly, we analysed data from the Swedish National Diabetes Registry Swediabkids that 
registers almost 100% of all cases of diabetes in children 0-17 years old in Sweden and used 
onset before 6 months of age as a way of finding cases of NDM.  Also, we analysed data from 
the Swedish Neonatal Quality Register that records neonatal outcome in Sweden. Finally, we 
retrieved data from the National Patient Register that collects all in-patient diagnoses in 
Sweden. Both the Swedish Neonatal Quality Register and the National Patient Register use 
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the Swedish version of the International Classification of Diseases (ICD-10-SE) and we 
searched for the ICD-10-SE code Neonatal Diabetes P70.2. 
Ethics 
This study was approved by the Regional Ethics Committee (2016/1:12). Permission to use 
photographs was granted by the parents. 
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RESULTS 
Treatment with insulin, insulin pumps and CGM 
Intravenous insulin was started within the first two weeks of life for six of the children. One 
patient was diagnosed later and started receiving insulin therapy at 41 days of age (Table 1). 
Following the initial intravenous treatment period, delivering insulin using an insulin pump 
and monitoring glucose values with CGM was used in six patients.  
The insulin pump infusion set and the CGM sensor were placed on locations where 
subcutaneous fat was present, usually the thigh and the upper arm of the child. We did not put 
devices on the abdomen to avoid the risk of penetrating the peritoneal membrane. Preterm 
infants were kept on intravenous insulin until they reached a body weight of around 1000 
grams to enable us to safely insert the infusion set in subcutaneous tissue. The smallest patient 
weighed 938 grams when starting treatment with an insulin pump at the age of 32 days 
(Figure 1).  
For use in the pump, insulin was diluted as described by the manufacturer. A one-step dilution 
1:10 to give a concentration of insulin 10 U/ml was used for the later patients in the cohort 
(Table 1). Settings of pumps do not allow for diluted insulin and pumps were marked to 
illustrate that the actual dose was 10% of displayed dose. Tubings were flushed with the pump 
disconnected from the patient twice a day to limit effects of degeneration of insulin in the 
tubes due to slow speed of infusion and the heat provided by incubators or warming 
mattresses. The insulin in the pump was changed every 24 hours and infusion sets were 
changed every third day.  
Patients were treated with a basal rate of insulin in addition to bolus doses given at set glucose 
threshold values, for example 10 mmol/l, or at time of meal. Breastfed children were weighed 
before and after feeding to determine the bolus dose of insulin, using individual ratios for 
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need of insulin in relation to carbohydrate intake, estimating 7 g of carbohydrate per 100 g of 
breast milk (21). 
Bolus doses were given after feeding or arbitrarily divided in two fractions, before and after 
feeding, that together made up the desired dose of insulin. A typical total daily dose of insulin 
was 0.3 U/kg body weight (range 0.2-1.4 (U/kg/day). Based on the CGM registrations, the 
meal boluses were adjusted and typically made up 70-80% of the total insulin. For a patient 
weighing one kilo, the basal dose could therefore be 0.0025 U/h which made the dilution of 
insulin described above necessary. When terminating treatment, the basal insulin administered 
by the pump was gradually lowered and stopped first, and the boluses kept until the child was 
not hyperglycaemic after meals. 
The sensor for CGM was placed in subcutaneous tissue before or at the time of starting 
insulin pump treatment (Figure 2). The sensor was changed according to the manufacturer’s 
recommendations after 5-7 days or earlier if the insertion place showed signs of skin irritation. 
Transparent self-adherent dressings were used to support the sensor and its cannula and yet 
allow inspection. The CGM readings were checked every hour until stabilised, and then 
before and two hours after every meal, if applicable. For patients on continuous feeding the 
sensor was checked every second hour. Goals for glucose control were set to 6-12 mmol/l at 
the start of treatment, regardless of whether the patient had meals or continuous feeding, and 
goals were narrowed to 4-8 mmol/l after a period individualised for each patient. We were 
unable to make comprehensive statistical analyses of glucose control, but an example of CGM 
registration and effect of insulin bolus doses is shown in Figure 3. The staff of the NICU staff 
was instructed to calibrate the CGM against plasma-glucose every eight hours, preferably 
when values were stable, and we expected a delay of 10 minutes for changes in plasma-
glucose to be noticed by the sensor. Urine from each diaper was checked for ketones to 
determine the renal threshold for hyperglycaemia. 
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For safety, we developed routines and bed-side protocols for monitoring of pumps and CGM 
in collaboration between the NICU and the Pediatric Diabetes Unit.  
 
No severe side-effects, such as severe hypoglycaemia or local infection was observed. Both 
parents and staff handled the technical devices well after initial training. No patient continued 
with subcutaneous injections or intravenous insulin after having used an insulin pump.  
Insulin pump treatment was terminated when insulin was no longer needed to maintain 
glucose within targets.  Four patients left the NICU and continued treatment in their homes 
with insulin pumps with support from the hospital. The 24-hour technical support service by 
the manufacturers of pumps and CGM was useful. No patient was transferred to treatment 
with oral anti-diabetic drugs as results of genetic analyses were not available before the 
treatment with insulin was terminated. 
 
Laboratory and genetic tests   
Six investigated patients had none of the antibodies, Islet Antigen 2 or Glutamic acid 
decarboxylase commonly seen in type 1 diabetes mellitus, and one patient was not tested. Six 
patients had no blood-ketones at diagnosis and patient one was not tested for ketones. Results 
on serum-insulin, plasma-glucagon and faeces-elastase were not complete or difficult to 
interpret due to unclear relation to plasma-glucose and nutrition (data not shown).  
A mutation was identified in five patients (Table 1) and this included all patients born after 30 
weeks of gestation. No mutations were identified in the two most preterm patients; analyses 
for mutations in KCNJ11, ABCC8 and INS were negative in patient one and mutations in 
KCNJ11, ABCC8, GK, HNF1 alfa and HNF4 alfa or alterations in 6q24 were not identified in 
patient two. Patients five and six were siblings with an identical 6q24 paternal duplication and 
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the same mutation could be identified in the father and paternal grandfather. The remaining 
three children had an ABCC8 mutation (Table 1). The mutation in patient three was 
previously known and was identified also in the patient´s father, whereas the mutation found 
in patient four was novel and identified also in the patient´s father with diabetes and therefore 
likely associated with NDM. The mutation in patient seven was a novel missense mutation 
where other genetic abnormalities were not identified. 
Two children had one or both parents born outside a Nordic (Denmark, Finland, Iceland, 
Norway, Sweden) country: the parents of patient one were born in Iraq and related, and 
patient four, with likely paternal inheritance of NDM, had a mother from Colombia.  
All patients could be taken off insulin and were diagnosed as TNDM. To date, patient five 
was diagnosed with diabetes again at 4.5 years of age. A developmental delay was suspected 
in patient seven, but the patient moved from the area and was not available for investigation 
or follow up. No patient was diagnosed with a syndrome associated with NDM.  
 
Incidence of Neonatal Diabetes 
In the 19-year study period 1 January 1998 to 31 December  2016 seven cases of neonatal 
diabetes were treated at our clinic (Table 1).  The number of deliveries in the four obstetric 
clinics that would refer patients to us in the 19 years of the study were 306637 (20). We were 
unable to take into consideration if children were twins, early deaths or stillbirths.  Around 
1% of deliveries are multiple births which would add 3000 children to the figure and we used 
an estimated total number of births 310000 for our calculations. This corresponds to an 
estimated incidence of NDM of one in 45000 children. In the Swedish National Diabetes 
Registry Swediabkids a total number of 17 children with an onset of diabetes before six 
months of age were registered in Sweden in the available period 1 May 2005 to 31 December 
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2016 (11.5 years).  All patients in this study were included. In Sweden, a total number of 
1337165 children were born from 1 January 2005 to 31 December  2016 (22) and this 
corresponds to an incidence of neonatal diabetes of one in 80000 children. In the Swedish 
Neonatal Quality Register and the National Patient Register, analyses could be made for the 
respective hospitals. The Swedish Neonatal Quality Register identified six cases and the 
National Patient Register identified five cases of NDM from the hospitals in the study area. 
No patient that was not included in our study was identified, hence supporting that our study 
recorded all cases in the study area. 
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DISCUSSION 
NDM is a heterogenous disease where a genetic mutation can be identified in more than 80% 
of cases. Looking at large series of children with NDM undergoing comprehensive genetic 
testing, about 50% are TNDM, 40% PNDM and 10% syndromic (6,23). The incidence of 
NDM in our study was one in 60000 if we only considered the five cases where a mutation 
was identified, or one in 45000 if we also include cases where a mutation was not identified, 
and relate this to all births in the study area during the 19 years of study. In our study, the 
incidence of NDM was therefore higher than the minimal incidence of one in 90000 reported 
from Italy (3) and much higher than previously reported from Europe (1-2). In the comparison 
we made in Swedish quality registers, the reported incidence of children with diabetes with an 
onset before six months of age from the Swedish National Diabetes Registry Swediabkids was 
one in 80000. The hospital-based quality registries, the Swedish Neonatal Quality Register 
and the National Patient Register had a slight under-reporting as one and two of the cases in 
this study were missing in each register, respectively.  We therefore conclude that the 
incidence of one in 45000 that we report in this study represent a minimal incidence that 
could be slightly higher if cases were missed by the study and the three quality registries. On 
the other hand, all cases in our study were TNDM. The variation in incidence and proportion 
of TNDM to PNDM may reflect referral biases such as patients with TNDM to a lesser extent 
being identified and referred for testing, as well as true variations in these hereditary 
conditions. 
Clinicians should be aware of NDM. In our study mutations were identified in all cases born 
from gestational age 30 weeks. In the literature, it is pointed out that also among the most 
premature children with NDM, about one in three has a mutation (12) and hence genetic 
analysis should be performed for all cases. Genetic diagnosis is helpful for the family to 
evaluate the situation and prognosis, including the risk for later diabetes in cases that turn out 
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to be TNDM. Most importantly, a genetic analysis also identifies the children where insulin 
can be replaced by superior treatment with sulphonylurea in oral preparations (8). 
In modern neonatal care, parents are much involved in the care of their infant, also in the high 
technology setting of the NICU and this is regarded beneficial to the family and their child 
(24). This patient-centred care is also a part of modern paediatric diabetes care and parents of 
the children with NDM were gradually taught to use the insulin pump and CGM. Four 
patients were able to go home while still using these technical devices. We developed 
structures for safe care and handling of insulin pumps in the NICU (guidelines and bed-side 
reports) and efforts were made to collaborate with the high number of staff that is involved in 
the care of an infant in the NICU. In Sweden, the cost of these devices is covered by the 
public health care and costs were therefore no issue for the individual families. 
In conclusion, we argue that using the technical devices, that are part of standard care for 
patients with type 1 diabetes mellitus, is safe in children with NDM and promotes improved 
glucose control. It also reduces the problems of intravenous access and frequent blood 
sampling. Some of the staff, but not all, need to have high technical skills, experience and 
familiarity with the technology used. The most important practical features were ability of the 
pump to deliver small doses of insulin and the size, length and insertion angle of cannulas and 
tubing. Also, NDM was more common than previously reported. Further studies providing 
detailed data on metabolic control, growth and comparisons between different treatments 
modules would be very beneficial to aid clinicians treating these rare cases. 
 
 
Strengths and limitations 
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The strength of this study was that we described incidence and a technical development over 
almost two decades. We used a known number of deliveries as our denominator. A limitation 
was that although we claimed to have identified all cases from 1998 when we started 
collecting the information, cases may have been missed which would make the incidence 
higher. Also, in the Swedish National Diabetes Registry Swediabkids cases of PNDM may 
have been more likely to be included than TNDM, but this also would have resulted in a 
higher incidence. The three quality registries have all become more accurate with time but 
there may have been under-reporting, at least in the earlier years which also would have 
increased incidence. Two patients in our study were siblings which may have inflated our 
figures by one case and compensating for this would result in a minimal incidence of four 
cases with mutations in 310000 births, which resembles the Italian data (3). During the study 
period, there was a technical development that led us to use various technical devices and for 
each patient we chose what seemed most convenient and appropriate among available devices 
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ABBREVIATIONS 
CGM  Continuous glucose monitoring  
ICD-10-SE International Classification of Diseases, version Sweden 10 
NDM   Neonatal diabetes mellitus 
NICU  Neonatal intensive care unit  
PNMD  Permanent neonatal diabetes mellitus  
TNDM  Transient neonatal diabetes mellitus 
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TABLE 1. Characteristics of patients in order of increasing birth weight  
 
Patient 1 2 3 4 5 6 7 














Birth year 2016 2010 2007 2014 2007 2011 2012 
Sex Male Male Male Female Female Male Male 
Birth weight (grams) 642 777 1455 1881 2200 2355 3500 
Small for gestational age No Yes No Borderline Yes Borderline No 
pH at diagnosis 7.08 Normal Normal Normal Normal Normal Normal 
C-peptide at diagnosis 
(reference 0.25-1 nmol/l) 
0.43 0.35 0.06 0.72 0.21 0.28 Missing 
value 
Plasma-glucose at diagnosis 
(reference <11 mmol/l) 
























Age at start of insulin  
(days) 
1 12 4 2 4 5 41 
Age at start of insulin pump  
(days) 
45 54 7 13 9 5 43 
Age at stopping insulin 
(days) 
59 57 145 17 50 22 116 
Insulin and  















Insulin pump  Paradigm 
Veo 










Pump infusion set Silhouette No pump Silhouette Silhouette Silhouette Silhouette Silhouette 
Continuous glucose 
monitoring system  
DexComG5 
 
MiniLink Microdialysis MiniLink MiniLink MiniLink MiniLink 
Glucose sensor DexComG4 Sof Microdialysis Enlite Sof Enlite Sof 
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FIGURE LEGENDS 
 
Figure 1. Patient 1 at 938 g at onset of treatment with insulin pump (Medtronic Veo) on upper 
arm and Continuous Glucose Monitoring (DexCom5) on leg. Shown with permission from 
parent.  
 
Figure 2: MiniLink in right thigh of patient number 4. The diaper of the child is to the right 
and the examiner holds the knee. Shown with permission from parent. 
 
Figure 3: Computer download for patient six showing effect of bolus doses given with insulin 
pump at meals and resulting effect on glucose measured with continuous glucose monitoring. 
The patient no longer has a basal insulin dose. Note that insulin was diluted 1:10 and actual 
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